Combination of antiplatelet agents has been poorly evaluated. In a mouse model of chronic immune-mediated hepatitis B that progresses to hepatocellular carcinoma, the treatment with low-dose aspirin and clopidogrel caused a marked reduction in the development of hepatomas. Also, the overall mass of the hepatomas resulted to be lower in mice treated with the combination therapy. At the time when 75% of vehicle-treated mice were found dead, only 20% of the animals treated with aspirin plus clopidogrel had died. Notably, the combined antiplatelet treatment did not cause significant bleeding side effects in these animals (Sitia et al., 2012).